The company soon plans to start a phase 3 trial for the vaccine, mRNA-1038, in adults 50 and older. The vaccine, in early and mid-stage studies, generated a similar or greater immune response relative to two current flu shots. In terms of SARS-CoV-2, it achieved neutralizing antibody titers similar to the bivalent COVID-19 booster. No new side effects were identified beyond those seen with standalone flu and COVID-19 shots.
Moderna aims to secure regulatory approval for the vaccine in 2025.
“We are excited to move combination respiratory vaccines into Phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses,” the company’s CEO, Stephane Bancel, said in a statement.
Pfizer is also working to develop a combination shot targeting the respiratory viruses.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
